Suspension of marketing Iclusig (Ariad Pharma) in US
Ariad Pharmaceuticals, Inc. announced that it is temporarily suspending the marketing and commercial distribution of Iclusig (ponatinib), a treatment for patients with resistant or intolerant Chronic Myeloid Leukemia (CML) and Philadelphia-chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy. The Company�s actions have been taken in response to a request by the FDA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins